Advertisement

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      We examined the long-term effect of pravastatin, a new potent inhibitor of endogenous cholesterol biosynthesis, on glucose and lipid metabolism in hyperlipidemic NIDDM. Ten patients (5 on sulfonylurea, 5 on diet) were studied over 12 months. Five were WHO type IIa and 5 were type IIb. Blood was taken before and then 1, 6 and 12 months after initiating 10 or 20 mg daily of pravastatin. The cholesterol concentration in whole plasma and very low density lipoprotein (VLDL), plasma triglyceride and apolipoprotein (apo) B were all significantly decreased within the first month. These changes lasted for 1 year. High density lipoprotein (HDL)-cholesterol increased in the first month but returned to base line thereafter. Low density lipoprotein (LDL)-cholesterol tended to decrease in the first month, and was suppressed significantly from the 6th month (11%) to the 12th month (16%). The effect of pravastatin on LDL-cholesterol in NIDDM was slower and weaker than that published for non-diabetic hypercholesterolemia. Therefore, the mechanism by which pravastatin suppresses plasma cholesterol levels in these two conditions may differ. After 1 year, no adverse effects were noted on hematopoietic, hepatic or renal function. Blood glucose level, hemoglobin A1c and the insulin response to oral glucose were unchanged. In addition, serum creatine phosphokinase showed no abnormal increase. Careful ophthalmological examinations before and after pravastatin treatment revealed no development of new lenticular opacities. Thus, pravastatin appears to be a safe and effective drug for the long-term treatment of NIDDM with hypercholesterolemia.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kannel W.B.
        • Dawber T.R.
        • Kagan A.
        • Castelli W.D.
        • Gordon T.
        • McNamara P.M.
        Factors of risk in the development of coronary heart disease; six-year follow up experience — The Framingham study.
        Ann. Intern. Med. 1971; 74: 1
        • Gotto Jr., A.M.
        Status report — plasma lipids, lipoproteins and coronary heart disease.
        Atheroscler. Rev. 1979; 4: 17
        • Goldstein J.L.
        • Brown M.S.
        Familial hypercholesterolemia; identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol.
        in: 7th edn. Proc. Natl. Acad. Sci. USA. 70. 1973: 2804
        • Brown M.S.
        • Kovanen P.T.
        • Goldstein J.L.
        Regulation of plasma cholesterol by lipoprotein receptors.
        Science. 1987; 212: 628
        • Tsujita Y.
        • Kuroda M.
        • Shimada Y.
        • Tanzawa K.
        • Arai M.
        • Kaneko I.
        • Tanaka M.
        • Masuda N.
        • Tarumi C.
        • Watanabe Y.
        • Fujii S.
        CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.
        Biochim. Biophys. Acta. 1986; 877: 50
        • Nakaya N.
        • Homma Y.
        • Tamachi H.
        • Goto Y.
        The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers.
        Atherosclerosis. 1986; 61: 125
        • Kazumi T.
        • Yoshino G.
        • Kasama T.
        • Iwatani I.
        • Iwai M.
        • Morita S.
        • Baba S.
        Effect of CS-514, a new inhibitor of HMG-CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
        Horm. Metab. Res. 1986; 18: 654
        • Yoshino G.
        • Kazumi T.
        • Iwai M.
        • Kasama T.
        • Iwatani I.
        • Matsuba K.
        • Inui A.
        • Uenoyama R.
        • Yokono K.
        • Otsuki M.
        • Baba S.
        CS-514 suppresses plasma triglyceride in hypertriglyceridemic subjects without modifying a lipoprotein structure model.
        Horm. Metab. Res. 1987; 19: 513
        • Nakaya N.
        • Homma Y.
        • Tamachi H.
        • Shigematsu H.
        • Hata Y.
        • Goto Y.
        The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
        J. Am. Med. Assoc. 1987; 257: 3088
        • Mabuchi H.
        • Kamon N.
        • Fujita H.
        • Michishita I.
        • Takeda M.
        • Kajinami K.
        • Itoh H.
        • Wakasugi T.
        • Takeda R.
        Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
        Metabolism. 1987; 36: 475
        • Yoshino G.
        • Kazumi T.
        • Iwai M.
        • Iwatani I.
        • Matsuba K.
        • Kasama T.
        • Matsushita M.
        • Otsuki M.
        • Baba S.
        Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
        Atherosclerosis. 1988; 71: 95
        • Jarrett R.J.
        • Keen H.
        Diabetes and atherosclerosis.
        in: Keen H. Jarrett R.J. Complications of Diabetes. Edward Arnold, London1975: 179-204
        • West K.M.
        Epidemiology of Diabetes and its Vascular Lesions.
        in: Elsevier/North-Holland, New York1978: 360-374
        • Sosenko J.M.
        • Breslow J.L.
        • Miettinen O.S.
        • Gabbay K.H.
        Hyperglycemia and plasma lipid levels. A prospective study of young insulin-dependent diabetic patients.
        N. Engl. J. Med. 1980; 302: 650
        • Mattock M.B.
        • Fuller J.H.
        • Maude P.S.
        • Keen H.
        Lipoproteins and plasma cholesterol esterification in normal and diabetic subjects.
        Atherosclerosis. 1979; 34: 437
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        Distribution and chemical composition of ultracentrifugally, separated lipoproteins in human serum.
        J. Clin. Invest. 1955; 34: 1345
        • Gochman N.
        • Schmitz J.M.
        Application of a new peroxidase indicator to specific, automated determination of glucose with glucose oxydase.
        Clin. Chem. 1972; 18: 943
        • Morgan C.R.
        • Lazarow W.
        Immunoassay of insulin: two antibody system. Plasma insulin levels of normal, subdiabetic and diabetic rats.
        Diabetes. 1963; 12: 115
        • Koenig R.J.
        • Peterson C.M.
        • Jones R.L.
        • Sandek C.
        • Lehman M.
        • Cerami A.
        Correlation of glucose regulation and hemoglobin AIC in diabetes mellitus.
        N. Engl. J. Med. 1976; 285: 417
        • Sakai Y.
        • Itakura K.
        • Kanada T.
        • Ebata N.
        • Suga K.
        • Aikawa H.
        • Nakamura K.
        • Sata T.
        Quantitation of apolipoprotein A-I in pooled human serum by single radial immunodiffusion and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
        Anal. Biochem. 1984; 137: 1
        • Ishibashi S.
        • Murase T.
        • Takahashi K.
        • Mori N.
        • Kawakami M.
        • Takaku F.
        Plasma apolipoprotein CII levels in hypertriglyceridemia.
        Metabolism. 1986; 35: 781
        • Mancini G.
        • Carbonara A.O.
        • Heremans J.F.
        Immunochemical quantitation of antigens by single radial immunodiffusion.
        Immunochemistry. 1965; 2: 235
        • Liebow I.M.
        • Hallestein H.K.
        • Miller M.
        Arteriosclerotic heart disease in diabetes mellitus.
        Am. J. Med. 1955; 18: 438
        • Yoshino G.
        • Kazumi T.
        • Kasama T.
        • Iwatani I.
        • Iwai M.
        • Inui A.
        • Otsuki M.
        • Baba S.
        Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics.
        Diab. Res. Clin. Prac. 1986; 2: 179
        • Yoshino G.
        • Kazumi T.
        • Uenoyama R.
        • Inui A.
        • Kasama T.
        • Iwatani L.
        • Iwai M.
        • Yokono K.
        • Otsuki M.
        • Baba S.
        Probucol versus eptastatin in hypercholesterolemic diabetics.
        The Lancet. 1986; I: 740
        • Yoshino G.
        • Kazumi T.
        • Kasama T.
        • Iwai M.
        • Iwatani I.
        • Matsuba M.
        • Matsushita M.
        • Baba S.
        Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats.
        Atherosclerosis. 1988; 73: 191
        • Grundy M.S.
        • Vega L.L.
        Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
        J. Lipid Res. 1985; 26: 1464
        • Kovanen P.T.
        • Bilheimer D.W.
        • Goldstein J.L.
        • Jaramillo J.J.
        • Brown M.S.
        Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.
        in: 7th edn. Proc. Natl. Acad. Sci. USA. 78. 1981: 1194
        • Bilheimer D.W.
        • Grundy S.M.
        • Brown M.S.
        • Goldstein J.L.
        Mevinolin and colestipol stimulate receptormediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
        in: 7th edn. Proc. Natl. Acad. Sci. USA. 80. 1983: 4124
        • Kiesebach A.H.
        • Alfarsi S.
        • Evans D.J.
        • Adams P.W.
        Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus.
        J. Clin. Invest. 1983; 71: 655
        • Steinbrecher U.P.
        • Witztum J.L.
        Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism.
        Diabetes. 1984; 33: 130
        • Garg A.
        • Grundy S.M.
        Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
        N. Engl. J. Med. 1988; 318: 81
        • Tobert T.A.
        New development in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
        Circulation. 1987; 76: 354